Psoriasis: risankizumab tops adalimumab in phase 3 trial

Key results

• Risankizumab was associated with better efficacy compared with adalimumab at week 16.
  • 72% vs 47% of patients achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI-90) (P<.0001>
  • 84% vs 60% of patients achieved static Physician’s Global Assessment (sPGA) scores of clear or almost clear (P<.0001>
• Adalimumab intermediate responders who switched to risankizumab at week 16 showed a higher PASI 90 rate (66% vs 21%; P<.0001 and spga clear rate vs compared with patients who continued adalimumab at week>
• Risankizumab and adalimumab were associated with similar rates of adverse events at week 16 (56% vs 57%).

Study design

• 605 patients with moderate-to-severe plaque psoriasis were randomly assigned to risankizumab (n=301) or adalimumab (n=304) through 16 weeks.
• At week 16, 102 patients with an intermediate response to adalimumab were re-randomly assigned to risankizumab (n=51) or adalimumab (n=51) through week 44.
• Funding: AbbVie, Boehringer Ingelheim.

Limitations

• Prolonged interval between final dose and final assessment.